Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma

Multicenter Study of Phase II With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet ®), Vincristine, Prednisone, (R-COMP) in Non-Hodgkin's Lymphoma Diffuse Large B Cell in Cardiopathic Patients

This is a multicenter study phase II, open-label for cardiopathic patients affected by Non-Hodgkin's lymphoma diffuse large B cell CD20 + grade IIIb follicular. The purpose is to study the feasibility of R-COMP in this cohort of patients.

Inclusion Criteria:

• NHL histological diagnosis of diffuse large B cell CD20 + (de novo or shift from low-grade NHL if not pretreated), grade IIIb follicular NHL;
• Age >= 18 years;
• Presence of at least 1 factor that defines the cardiopathy;
• Life expectancy > 3 months;
• In the case of women of childbearing age absence of pregnancy at the beginning of the chemotherapy;
• Written informed consent.

Exclusion Criteria:

• Histology different from NHL diffuse large cell CD20 + or follicular IIIb
• Age < 18 years
• Inability to sign informed consent;
• HIV positivity;
• Patients HBsAg positive;
• AST/ALT > 2 times the standard;
• Bilirubin > 2 times the standard;
• Creatinine > 2.5 mg / dl;
• Location of CNS disease;
• Pregnancy ongoing;
• Damage to that organ or medical problems that could interfere with the therapy;
• Current uncontrolled infection;
• Senile dementia